VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
- Phase 3-ready asset expands VistaGen?s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
- Novel PH94B nasal spray expected to enter pivotal Phase 3 development for as-needed (PRN) treatment of Social Anxiety Disorder (SAD) in the first half of 2019; positioned to drive a paradigm shift towards rapid-acting treatment of SAD, without risk of addiction
- Patents on the use of PH94B nasal spray to treat SAD have been granted in the U.S., Europe, Japan, China, Korea and numerous other countries
Released September 13, 2018